Immunogenicity and Neutralization of Recombinant Vaccine Candidates Expressing F and G Glycoproteins against Nipah Virus

被引:0
|
作者
Moon, Seo Young [1 ]
Flores, Rochelle A. [2 ,3 ]
Yim, Min Su [1 ]
Lim, Heeji [1 ]
Kim, Seungyeon [1 ]
Lee, Seung Yun [2 ,3 ]
Lee, Yoo-kyoung [1 ]
Kim, Jae-Ouk [4 ]
Park, Hyejin [1 ]
Bae, Seong Eun [4 ]
Ouh, In-Ohk [1 ]
Kim, Woo H. [2 ,3 ]
机构
[1] Korea Dis Control & Prevent Agcy, Natl Inst Infect Dis, Korea Natl Inst Hlth, Div Vaccine Dev Coordinat,Ctr Vaccine Res, Cheongju 28159, Chungcheongbuk, South Korea
[2] Gyeongsang Natl Univ, Coll Vet Med, Jinju 52828, Gyeongsangnam D, South Korea
[3] Gyeongsang Natl Univ, Inst Anim Med, Jinju 52828, Gyeongsangnam D, South Korea
[4] Int Vaccine Inst, Sci Unit, Mol Immunol, Seoul 08826, South Korea
关键词
Nipah virus; recombinant vaccine; antigenicity; pseudotype neutralization assay; BATS; FUSION; BANGLADESH; OUTBREAK; HENDRA; DESIGN;
D O I
10.3390/vaccines12090999
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Nipah virus (NiV), of the Paramyxoviridae family, causes highly fatal infections in humans and is associated with severe neurological and respiratory diseases. Currently, no commercial vaccine is available for human use. Here, eight structure-based mammalian-expressed recombinant proteins harboring the NiV surface proteins, fusion glycoprotein (F), and the major attachment glycoprotein (G) were produced. Specifically, prefusion NiV-F and/or NiV-G glycoproteins expressed in monomeric, multimeric (trimeric F and tetra G), or chimeric forms were evaluated for their properties as sub-unit vaccine candidates. The antigenicity of the recombinant NiV glycoproteins was evaluated in intramuscularly immunized mice, and the antibodies in serum were assessed. Predictably, all homologous immunizations exhibited immunogenicity, and neutralizing antibodies to VSV-luciferase-based pseudovirus expressing NiV-GF glycoproteins were found in all groups. Comparatively, neutralizing antibodies were highest in vaccines designed in their multimeric structures and administered as bivalent (GMYtet + GBDtet) and trivalent (Ftri + GMYtet + GBDtet). Additionally, while all adjuvants were able to elicit an immunogenic response in vaccinated groups, bivalent (GMYtet + GBDtet) and trivalent (Ftri + GMYtet + GBDtet) induced more potent neutralizing antibodies when administered with oil-in-water nano-emulsion adjuvant, AddaS03. For all experiments, the bivalent GMYtet + GBDtet was the most immunogenic vaccine candidate. Results from this study highlight the potential use of these mammalian-expressed recombinant NiV as vaccine candidates, deserving further exploration.
引用
收藏
页数:18
相关论文
共 50 条
  • [41] A recombinant pseudorabies virus expressing rabies virus glycoprotein: Safety and immunogenicity in dogs
    Yuan, Ziguo
    Zhang, Shoufeng
    Liu, Ye
    Zhang, Fei
    Fooks, Anthony R.
    Li, Qianxue
    Hu, Rongliang
    [J]. VACCINE, 2008, 26 (10) : 1314 - 1321
  • [42] Construction and Immunogenicity of a Recombinant Pseudorabies Virus Expressing the Rabies Virus Glycoprotein and EGFP
    Han, Naijun
    Li, Yewei
    Sun, Chenglong
    Meng, Qingguo
    Song, Feifei
    Yang, Yang
    Zhang, Shoufeng
    Hu, Rongliang
    [J]. JOURNAL OF ANIMAL AND VETERINARY ADVANCES, 2012, 11 (04): : 567 - 571
  • [43] Development and laboratory evaluation of a competitive ELISA for serodiagnosis of Nipah and Hendra virus infection using recombinant Nipah glycoproteins and a monoclonal antibody
    Zhu, Wenjun
    Pickering, Bradley
    Smith, Greg
    Pinette, Mathieu
    Truong, Thang
    Babiuk, Shawn
    Kobasa, Darwyn
    Banadyga, Logan
    Yang, Ming
    [J]. FRONTIERS IN VETERINARY SCIENCE, 2023, 10
  • [44] Construction of a recombinant vaccine expressing Nipah virus glycoprotein using the replicative and highly attenuated vaccinia virus strain LC16m8
    Watanabe, Shumpei
    Yoshikawa, Tomoki
    Kaku, Yoshihiro
    Kurosu, Takeshi
    Fukushi, Shuetsu
    Sugimoto, Satoko
    Nishisaka, Yuki
    Fuji, Hikaru
    Marsh, Glenn
    Maeda, Ken
    Ebihara, Hideki
    Morikawa, Shigeru
    Shimojima, Masayuki
    Saijo, Masayuki
    [J]. PLOS NEGLECTED TROPICAL DISEASES, 2023, 17 (12):
  • [45] Inactivated Recombinant Rabies Virus Displaying the Nipah Virus Envelope Glycoproteins Induces Systemic Immune Responses in Mice
    Li, Zhengrong
    Zhu, Yanting
    Yan, Feihu
    Jin, Hongli
    Wang, Qi
    Zhao, Yongkun
    Feng, Na
    Wang, Tiecheng
    Li, Nan
    Yang, Songtao
    Xia, Xianzhu
    Cong, Yanlong
    [J]. VACCINES, 2023, 11 (12)
  • [46] Protection of dogs against canine distemper by vaccination with a canarypox virus recombinant expressing canine distemper virus fusion and hemagglutinin glycoproteins
    Pardo, MC
    Bauman, JE
    Mackowiak, M
    [J]. AMERICAN JOURNAL OF VETERINARY RESEARCH, 1997, 58 (08) : 833 - 836
  • [47] Identification and recombinant expression of vaccine candidates against invasive aspergillosis
    Rosenow, M.
    Asif, A. R.
    Oellerich, M.
    Gross, U.
    Reichard, U.
    [J]. MYCOSES, 2010, 53 (05) : 381 - 381
  • [48] Construction and Immunogenicity of Recombinant Vaccinia Virus Vaccine Against Japanese Encephalitis and Chikungunya Viruses Infection in Mice
    Zhang, Ying
    Han, Ji-cheng
    Jing, Jie
    Liu, Hao
    Zhang, He
    Li, Zhao-hui
    Jin, Ning-yi
    Lu, Hui-jun
    [J]. VECTOR-BORNE AND ZOONOTIC DISEASES, 2020, 20 (10) : 788 - 796
  • [49] Cell fusion and syncytia formation is mediated by oligosaccharide determinants of Nipah virus envelope F and G glycoproteins and can be blocked by lectins
    Levroney, E
    Aguilar, H
    Gurney, K
    Valenzuela, H
    Baum, LG
    Lee, BH
    [J]. GLYCOBIOLOGY, 2003, 13 (11) : 831 - 831
  • [50] Construction and immunogenicity of an mRNA vaccine against chikungunya virus
    Liu, Jingjing
    Lu, Xishan
    Li, Xingxing
    Huang, Weijin
    Fang, Enyue
    Li, Wenjuan
    Liu, Xiaohui
    Liu, Minglei
    Li, Jia
    Li, Ming
    Zhang, Zelun
    Song, Haifeng
    Ying, Bo
    Li, Yuhua
    [J]. FRONTIERS IN IMMUNOLOGY, 2023, 14